Centene Corporation has made a notable recovery in the healthcare market since facing challenges in 2025, including high medical costs. The company reported strong first-quarter 2026 results with adjusted earnings per share (EPS) of $3.37, surpassing the Zacks Consensus Estimate by 80.2%. Revenues reached $49.9 billion, representing a 7.1% year-over-year increase. Centene’s total projected revenues for 2026 are between $187.5 billion and $191.5 billion.
The firm generated $4.4 billion in operating cash flow last quarter and reduced its total debt by $1 billion. The renewed growth trajectory is backed by a strong position in Medicaid and an expanding Medicare market, with a notable boost from Texas Medicaid expansion. Centene is ranked #1 (Strong Buy) by Zacks and is one of the top 10% of industries, suggesting a favorable outlook over the next 3 to 6 months.
As of now, Centene’s stock has rebounded significantly, trading near its 52-week high after more than doubling from its lows in 2025. Analysts are optimistic, with the Zacks Consensus Estimate for 2026 EPS rising 15.28% in the last two months, projecting a 66.8% year-over-year increase.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
